NL-OMON26966尚未招募不适用
Patients on osimertinib with EGFR mutation exon 20, non-T790M. The position-20 trial.
niversity Medical Center Groningen (UMCG)0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Provision of informed consent prior to any study specific procedures
- •2.Patients must be ≥ 18 years of age.
排除标准
- •1.Presence of a T790M mutation or other tumour driven mutations, translocations or amplifications (e.g. common EGFR mutations, KRAS, BRAF V600E, ALK, ROS1)
- •2.Patient is unwilling and unable to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
研究者
相似试验
进行中（未招募）
1 期
Patients on osimertinib with EGFR mutation exon 20, non-T790M in lung cancer. The position-20 trial.Patients on osimertinib with EGFR mutation exon 20, non-T790M in lung cancer. The position-20 trial.MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004734-28-NLniversity Medical Center Groningen15
招募中
2 期
Patients on osimertinib with EGFR mutation exon 20, non-T790M in lung cancer. The position-20 trial.10038666Non-small cell lung cancerNL-OMON55798niversitair Medisch Centrum Groningen15
已完成
2 期
ncommon EGFR mutations conducted with Osimertinib in patients with NSCLC: A phase 2 studyAdvanced / recurrent non-small cell lung cancer (NSCLC)JPRN-jRCTs071200002Kubota Kaoru40
招募中
1 期
ovel treatment for people with lung cancer harbouring a specific mutatioEUCTR2018-001863-21-NOVestre Viken Hospital Trust100
进行中（未招募）
1 期
ovel treatment for people with lung cancer harbouring a specific mutatioEUCTR2018-001863-21-LTVestre Viken Hospital Trust100